8F8 Stock Overview
A clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SynAct Pharma AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.95 |
| 52 Week High | SEK 1.13 |
| 52 Week Low | SEK 0.53 |
| Beta | 0.65 |
| 11 Month Change | 25.79% |
| 3 Month Change | 26.29% |
| 1 Year Change | 73.86% |
| 33 Year Change | -92.80% |
| 5 Year Change | n/a |
| Change since IPO | -88.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8F8 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 23.3% | -1.1% | 1.1% |
| 1Y | 73.9% | -18.8% | 7.2% |
Return vs Industry: 8F8 exceeded the German Biotechs industry which returned -18.8% over the past year.
Return vs Market: 8F8 exceeded the German Market which returned 7.2% over the past year.
Price Volatility
| 8F8 volatility | |
|---|---|
| 8F8 Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8F8's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8F8's weekly volatility has decreased from 14% to 9% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 5 | Jeppe Ovlesen | synactpharma.com |
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.
SynAct Pharma AB Fundamentals Summary
| 8F8 fundamental statistics | |
|---|---|
| Market cap | €40.66m |
| Earnings (TTM) | -€13.41m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.0x
P/E RatioIs 8F8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8F8 income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 154.57m |
| Earnings | -SEK 154.57m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 18, 2025
| Earnings per share (EPS) | -3.74 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 8F8 perform over the long term?
See historical performance and comparison